Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Oral Drug Delivery Systems: Delayed-Release Systems

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CXCL6 exacerbates metabolic dysfunction-associated steatohepatitis by suppressing LPIN1-mediated fatty acid oxidation in hepatocytes.

International journal of biological sciences·2026

Same author

Local drug delivery for oral squamous cell carcinoma under oral cavity.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026

Same author

Polydopamine-mediated multi-stage delivery for precise local therapy of Helicobacter pylori-infected gastric ulcers.

Journal of controlled release : official journal of the Controlled Release Society·2026

Same author

Fecal microbiota transplantation in inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials (2020-2025).

Inflammopharmacology·2026

Same author

Theranostic advances in Alzheimer's disease: structure-guided design of near-infrared fluorescent probes targeting amyloid-β and cholinergic dysfunction.

RSC medicinal chemistry·2026

Same author

Once and thrice weekly interval training in adults with central obesity: a randomized controlled trial.

Nature communications·2026

Search research articles

Related Experiment Video

Updated: Jun 7, 2026

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

pH-sensitive Eudragit nanoparticles for mucosal drug delivery.

Jin-Wook Yoo¹, Namita Giri, Chi H Lee

¹Division of Pharmaceutical Sciences, University of Missouri, Kansas City, MO 64110, USA.

International Journal of Pharmaceutics

|October 26, 2010

Summary

This summary is machine-generated.

pH-sensitive nanoparticles made from Eudragit S-100 (ES) offer stable vaginal drug delivery. These biocompatible nanoparticles protect drugs in acidic conditions and release them at physiological pH, showing promise for targeted therapies.

More Related Videos

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices

Published on: January 30, 2026

Related Experiment Videos

Last Updated: Jun 7, 2026

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices

Published on: January 30, 2026

Area of Science:

Pharmaceutical Sciences
Biomaterials Science
Drug Delivery Systems

Background:

Vaginal drug delivery faces challenges due to acidic and enzymatic conditions, leading to poor drug stability.
Existing methods struggle to maintain therapeutic drug concentrations in the vaginal mucosal epithelium.

Purpose of the Study:

To develop biocompatible, pH-sensitive nanoparticles using Eudragit S-100 (ES) for enhanced vaginal drug delivery.
To protect loaded therapeutic compounds from degradation in the vaginal environment and ensure targeted release.

Main Methods:

ES nanoparticles were prepared using a modified quasi-emulsion solvent diffusion method.
Loading efficiencies for hydrophilic (sodium fluorescein) and hydrophobic (nile red) compounds were determined.
Drug release profiles at acidic and physiological pH were evaluated.
Cellular uptake and cytotoxicity of nanoparticles were assessed using confocal microscopy.

Main Results:

High loading efficiencies of 26% (hydrophilic) and 71% (hydrophobic) were achieved.
Nanoparticles demonstrated stability at acidic pH and rapid drug release at physiological pH.
Confocal studies confirmed cellular uptake by vaginal cells and pH-responsive drug release.
No cytotoxic activities were observed, indicating good biocompatibility.

Conclusions:

pH-sensitive ES nanoparticles are effective carriers for vaginal drug delivery, protecting drugs from degradation.
These nanoparticles facilitate targeted drug release in response to physiological pH changes.
The developed system shows significant potential for delivering various therapeutics, including microbicides, peptides, and proteins, specifically to the vaginal epithelium.